

Lasa Supergenerics Limited

Q1FY21 Earnings Conference Call

Wednesday, 12th August 2020 at 05:00 p.m.

Monday, 10th August 2020: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the first quarter ended June 30th, 2020 (Q1FY21).

It will organize an earnings conference call for analysts on Wednesday, 12th August 2020 @ 05:00 p.m to discuss the Company's Q1FY21 financial performance.

Dr. Omkar Herlekar - Chairperson & Managing Director will represent LASA Supergenerics Limited on the call.

The financial results are available on the corporate website - www.lasalabs.com

DETAILS OF THE CONFERENCE CALL

Timing	5:00p.m. IST on Wednesday,12 th August, 2020
Conference dial-in Primary number	+91 22 6280 1341 / +91 22 7115 8242
Local Access Number	+91-7045671221
Hong Kong Local Access Number	800964448
Singapore Local Access Number	8001012045
UK Local Access Number	08081011573
USA Local Access Number	18667462133

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more information contact:

Mr. Hitesh Wadhwani Mr. Gaurav Girdhar

Lasa Supergenerics Ltd. Concept Investor Relations

Tel: 7798888147 Tel: +022 40558934 E-mail: hitesh@lasalabs.com M: +91 7798232425

Email:gaurav.g@conceptpr.com